Bioxel Pharma (BIP.V) Announces Paclitaxel Purchase Agreement With CTI; Large Scale Paclitaxel Manufacturing Unit On-Stream In Second Quarter
10/19/2005 5:10:04 PM
Bioxel Pharma Inc. (TSX Venture: BIP), a leading manufacturer of naturally derived taxanes, today announced that it has entered into a purchase agreement for cGMP paclitaxel with Cell Therapeutics, Inc (CTI) of Seattle WA. The agreement value is at least CAN $1.2 million for cGMP paclitaxel originating from Bioxel's new large- scale paclitaxel manufacturing unit.
comments powered by